Asahi Kasei Corporation (TYO:3407)
1,630.50
-81.50 (-4.76%)
At close: Mar 9, 2026
Asahi Kasei Revenue
Asahi Kasei had revenue of 774.90B JPY in the quarter ending December 31, 2025, with 0.78% growth. This brings the company's revenue in the last twelve months to 3.04T, up 1.99% year-over-year. In the fiscal year ending March 31, 2025, Asahi Kasei had annual revenue of 3.04T with 9.06% growth.
Revenue (ttm)
3,039.32B
Revenue Growth
+1.99%
P/S Ratio
0.73
Revenue / Employee
60.36M
Employees
50,352
Market Cap
2,211.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3,037.31B | 252.43B | 9.06% |
| Mar 31, 2024 | 2,784.88B | 58.39B | 2.14% |
| Mar 31, 2023 | 2,726.49B | 265.17B | 10.77% |
| Mar 31, 2022 | 2,461.32B | 355.27B | 16.87% |
| Mar 31, 2021 | 2,106.05B | -45.60B | -2.12% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Resonac Holdings | 1,347.13B |
| Nippon Sanso Holdings | 1,334.48B |
| Mitsubishi Chemical Group | 4,161.98B |
| Nissan Chemical | 271.97B |
| Sumitomo Chemical Company | 2,407.78B |
| Tosoh | 1,023.76B |
| Kuraray | 808.45B |
| Nagase & | 950.99B |
Asahi Kasei News
- 11 days ago - Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris - Business Wire
- 11 days ago - Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases - GlobeNewsWire
- 12 days ago - Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds - Business Wire
- 19 days ago - Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases - Business Wire
- 5 weeks ago - Asahi Kasei Develops PFAS-Free PA66 Offering Low-Friction and High-Load Performance - Business Wire
- 2 months ago - ZOLL Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation LifeVest® WCD and Rollout of the Most Comfortable LifeVest Garment Ever, Reinforcing Position as Leader in WCD Category - Business Wire
- 2 months ago - Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark - Business Wire
- 2 months ago - Asahi Kasei Microdevices and Aizip Deliver Transformative AI-Enhanced Sensing Solutions - Business Wire